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1. Introduction 
Tumor suppressor genes (TSGs) protect normal cells from tumorigenesis (Lasko et al., 1991; 
Sherr, 2004). Except in cases of haploinsufficiency, heterozygosity for a non-functional TSG 
allele protects a cell from tumor formation because the functional TSG allele produces a 
functional protein. Loss of heterozygosity (LOH) is a mechanism by which the remaining 
wild type tumor suppressor allele is lost, resulting in tumor formation (Lasko et al., 1991; 
Sherr, 2004). Loss of TSG expression may also occur by epigenetic silencing. The probability 
of a "second hit" follows a Poisson distribution with the number of tumors and time of 
incidence being variable in heterozygous carriers (Shao et al., 1999). 
Many TSGs have been identified. Such genes play roles in many cellular functions including 
cell cycle checkpoint control, mitogenic signaling pathways, protein turnover, DNA 
damage, hypoxia and other stress responses (Sherr, 2004). Surprisingly, the SdhB, SdhC, and 
SdhD subunits of the metabolic enzyme succinate dehydrogenase (SDH), have also been 
identified as TSGs for neuroendocrine tumors such as paraganglioma (PGL) and 
pheocheomocytoma (PHEO).  
PGLs are rare (1:300,000) tumors of neuroectodermal origin derived from paraganglia, a 
diffuse neuroendocrine system dispersed from the base of the skull to the pelvic floor 
(Baysal, 2002). PGLs are highly vascularized tumors that can originate in either the 
sympathetic or parasympathetic nervous systems (Baysal, 2002; Pacak et al., 2001).  
Patients with PGL tumors that secrete catecholamines present symptoms of catecholamine 
excess including palpitations. The predominant clinical features of nonchromaffin PGLs are 
cranial nerve palsies and tinnitus; however, a small proportion of these nonchromaffin PGLs 
secrete catecholamines (Dluhy, 2002). A hereditary PGL predisposition is involved in at least 
30% of cases (Maher & Eng, 2002; Bryant et al., 2003). Individuals with familial 
predisposition display at least 40% penetrance and a more severe presentation than those 
with the sporadic form of the disease. Extra-adrenal pheochromocytomas are estimated to 
be malignant in 40% of cases (Young et al., 2002). There is currently no effective cure for 
malignant PGL. 
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Five genes encoding subunits of the succinate dehydrogenase (SDH) complex (SdhA, SdhB, 
SdhC, and SdhD) (Astuti et al., 2001; Baysal et al., 2000; Niemann & Muller, 2000; Burnichon 
et al.) or the enzyme responsible for SdhA flavination (Kaelin, 2009; Hao et al., 2009) have 
been identified as tumor suppressor genes in familial PGL. Sdh gene defects may also be the 
cause of sporadic head and neck PGLs where deletions at the same or closely related loci 
(11q13 and 11q22-23) are observed (Bikhazi et al., 2000). The remaining half of familial PGLs 
result from inherited mutations associated with von Hippel-Lindau (VHL) syndrome, 
multiple endocrine neoplasia type 2 (MEN 2), or neurofibromatosis genes (Inabnet et al., 
2000; Bryant et al., 2003).  
The SDH complex catalyzes the oxidation of succinate (Su) to fumarate (Fu) in the 
tricarboxylic acid (TCA) cycle and delivers the resulting electrons through various carriers 
to the ubiquinone pool of the electron transport chain. These electrons are ultimately 
donated to oxygen to generate water in the process that forms a proton gradient across the 
inner mitochondrial membrane for ATP production. The porcine SDH complex (Fig. 1) has 
been studied by X-ray crystallography (Sun et al., 2005). The largest subunit, SdhA, is a 
flavoprotein of 70 kDa that contains the SDH active site and FAD moiety. A smaller subunit, 
SdhB is an iron-sulfur protein of 30 kDa carrying three dissimilar iron clusters, [2Fe-2S]2+,1+, 
[4Fe-4S]2+,1+, and [3Fe-4S]1+,0+. SdhA/B are anchored to the membrane by SdhC and SdhD (15 
kDa and 12.5 kDa, respectively), which coordinate a heme group and possess a ubiquinone 
binding site essential for electron transport into the respiratory chain.  
 
 
Fig. 1. X-ray crystal structure of SDH complex (Sun et al., 2005). Four subunits labeled and 
indicating the flavin of the catalytic A subunit (FAD), iron-sulfur clusters of the B subunit 
(FeS), and co-enzyme Q (Q) near the C and D subunits. 
A broad spectrum of Sdh mutations has been reported in familial PGL. Mutations in SdhB 
and SdhC lead to non-imprinted autosomal dominant inheritance of familial PGL. Mutations 
in SdhD demonstrate imprinted paternal autosomal dominant inheritance (Baysal et al., 
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2002). The range of mutations in SDH subunit genes identified in familial PGL suggests that 
loss of function of SDH subunits is the common cause of PGL.  
Familial PGL is particularly fascinating because the causative genetic defects in SDH block 
the TCA cycle, enforcing upon the tumor an obligatory Warburg effect (Warburg, 1956). 
Thus, PGL tumor cells must apparently rely on glycolysis as an inefficient source of ATP. 
Familial PGL thus perfectly exemplifies the aerobic glycolysis commonly observed in 
cancer, and studies of PGL have the potential to reveal management strategies for all cancers 
that rely on glycolysis rather than the TCA cycle (Kaelin, 2009).  
PGL causation may involve HIF1 activation and other epigenetic effects. Cells carefully 
regulate oxygen uptake, and respond to hypoxia by altering gene regulation. The master 
regulator of these responses is the heterodimeric basic helix-loop-helix transcription factor 
Hypoxia-Inducible Factor 1 (HIF1). HIF1 regulation involves oxygen-dependent 
prolylhydroxylation (PHD), ubiquitin ligation, and proteasomal degradation of the HIF1ǂ 
subunit under normoxic conditions (Semenza, 2003). Prolylhydroxylation of HIF1ǂ requires 
oxygen, iron, and 2-ketoglutarate (2KG), and the reaction produces succinate (Su) as a 
byproduct. If oxygen becomes limiting, prolylhydroxylation is inhibited, and HIF1ǂ 
accumulates, translocates to the nucleus, and pairs with the constitutively expressed HIF1ǃ 
subunit. Thus, HIF1 stability is directly regulated by oxygen. Hypoxic genes stimulated by 
HIF1 include transporters for increased glucose import (allowing anaerobic growth by 
glycolysis) and genes encoding angiogenesis factors. HIF1 activation is correlated with 
tumor aggressiveness and therapy resistance. 
According to the succinate (Su) accumulation hypothesis (Lee et al., 2005; Maxwell, 2005; 
Selak et al., 2005; Smith et al., 2007; Favier & Gimenez-Roqueplo, 2010), the disruption of 
SdhB yields a catalytically inactive SdhA subunit and Su accumulates in the cell due to loss 
of SDH activity. Su diffuses to the cytoplasm where it acts as an inhibitor of the 2-
ketoglutarate (2KG)-dependent prolyl hydroxylase (PHD) enzymes that use molecular 
oxygen as a substrate to hydroxylate HIF1ǂ prolines for degradation when adequate oxygen 
is present. This class of enzyme reactions generates Su as a product, and is therefore 
susceptible to inhibition by elevated Su concentrations. Loss of SDH activity disables the 
TCA cycle and causes inappropriate HIF1 persistence due to Su inhibition of PHD enzymes. 
The resulting pseudohypoxic state is not tumorigenic in most cell types. However, it is 
hypothesized that chronic pseudohypoxic signaling is a mitogenic tumor initiator in 
neuroendocrine cells because these cells proliferate in a futile homeostatic attempt at a 
hormonal response to perceived hypoxia. Thus, inappropriate HIF1 persistence due to loss 
of SDH function in PGL drives tumorigenesis. HIF1 is therefore a novel target for therapy of 
PGL. 
Our working hypotheses are shown in Fig. 2. We hypothesize that tumorigenic effects of 
succinate accumulation are not limited to inhibition of prolyl hydroxylation (McDonough et 
al., 2006), but also include inhibition of histone demethylation by Jumoni domain (JHDM) 
enzymes (Klose et al., 2006), and inhibition of 5-methylcytosine hydroxylation by TET1 
(Tahiliani et al., 2009). Thus we are interested in model systems to probe how loss of SdhB 
acts as a tumorigenic trigger in neuroendocrine cells. 
To date there have been limited opportunities to understand SDH dysfunction in such 
animal models. Although no human PGL cell lines exist, various studies have been 
undertaken using PGL tumor tissue samples to understand the underlying biochemistry 
and genetics (Benn et al., 2006). Unfortunately, such patient samples are not numerous and 
no systematic approach has been taken in understanding the pathological biochemistry of 
PGL.  
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Mutations in genes encoding SdhB, SdhC, or SdhD in C. elegans, S. cerevisiae, and mammalian 
cell lines have been utilized to examine the reactive oxygen species (ROS) hypothesis and 
the succinate accumulation hypothesis (Guo & Lemire, 2003; Ishii et al., 1998; Ishii et al., 
2005; Lee et al., 2005; Oostveen et al., 1995; Selak et al., 2005). The only available mammalian 
PGL cell lines do not emulate the SDH familial form of PGL. For instance, rat PHEO cell line 
(PC12) (Tischler et al., 2004) and mouse PHEO cell lines (MPC) are available (Powers et al., 
2000). However, PC12 cells are derived from a spontaneous PHEO tumor with functional 
Complex II and MPC cells are derived from neurofibromatosis [(Nf1 +/- heterozygous] 
knockout mice (Tischler et al., 2004). During the course of this project a mouse model of 
SdhD deficiency was developed (Piruat et al., 2004). SdhD +/- mice were found to have 
decreased expression of SdhD and 50% SDH activity in various tissues relative to SdhD +/+ 
mouse tissues (Piruat et al., 2004). Although SdhD +/- mice were found to have carotid body 
glomus cell hyperplasia and organ hypertrophy, no PGL tumor formation was observed 
(Piruat et al., 2004; Bayley et al., 2009).  
 
 
Fig. 2. A. Normal tumor suppressor functions of Fe/O2/2KG-dependent dioxygenases in 
Hif-1ǂ degradation and epigenetic regulation of histone methylation and 5-methylcytosine 
hydroxylation. B. Proposed effects of succinate inhibition in PGL. Simple genetic models of 
Sdh mutant PGL come in the form of model organisms that contain defects in SDH subunits.  
We recently created and studied a yeast model lacking the SdhB subunit of Complex II 
(Smith et al., 2007). As expected for loss of a TCA enzyme, this yeast strain is dependent on 
glycolysis and is unable to survive on non-fermentable carbon sources. The yeast model has 
increased ROS and also shows accumulation of succinate. This succinate accumulation 
poisons at least two 2KG-dependent enzymes that produce succinate as a normal 
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byproduct. Succinate inhibition of such enzymes in mammalian systems (e.g. the 2KG-
dependent prolyl hydroxylase that modifies HIF-1ǂ and JHDMs) has been proposed as a 
completely novel metabolic mechanism of tumorigenesis. Further progress in 
understanding PGL and PHEO could be facilitated by development of animal models to 
allow testing of the ROS and succinate accumulation hypotheses and hypotheses related to 
environment, diet, and pharmaceutical interventions.  
Human SdhB mutations are not associated with a parent-of-origin effect (Baysal, 2001). It has 
also been observed that both SdhB- and SdhD-linked PGL tumors tend to lose SdhB 
expression and have enhanced SdhA abundance (Douwes Dekker et al., 2003). Thus, SdhB 
disruption creates an obvious goal for genetic models. Analysis of causative SdhB mutations 
in human PGL suggests that total loss of SdhB function is the common feature (Baysal, 2001; 
Baysal, 2002; Eng et al., 2003). 
Here we describe the generation of two heterozygous mouse lines carrying a disruption in 
one copy of SdhB. By analogy with human familial predisposition to PGL genetics (Baysal, 
2001; Baysal, 2002), mouse strains heterozygous for functional SdhB are hypothesized to 
display no phenotype, but to be predisposed to PGL development due to random loss of the 
second SdhB allele during development. Based on human PGL genetics, it was hypothesized 
that loss of the second SdhB gene would be oncogenic only in neuroendocrine cells. 
2. Materials and methods 
2.1 Creation of an SdhB targeting vector 
A recombinant targeting vector for mouse SdhB was designed and assembled according to 
standard procedures. SdhB-specific sequences were inserted into the commercial vector 
NTKV1901 (Stratagene) that carries Neo and TK genes for selection of targeted integrants. 
Briefly, two arms homologous to segments of the murine SdhB gene were amplified by PCR 
(Epicentre, Failsafe kit) from mouse genomic DNA with sets of primers containing two 
unique restriction sites. The left homologous arm (Scrambler A) was PCR-amplified with an 
upstream primer that contains a HindIII site, (LJM-2309: GCTAGCA2GCT2G2AGATA-
CAGCTCAGTCTGAGTG3) and a downstream primer that contains a XhoI site, (LJM-2310: 
GCTAGC2TCGAGCATC2A2CAC2ATAG2TC2GCAC2T). The Scrambler A PCR product was 
directly cloned into the targeting vector NTKV1901. The right homologous arm (Scrambler 
B) was PCR-amplified with an upstream primer containing a ClaI site (LJM-2311: 
GCTAGCATCGATG2TG2TGTC2TGCTGTGCTGT3GG) and a downstream primer containing 
a SacII site (LJM-2312: GCTAGC3GCG4A3G2TG4CAGACATAGTAC). The Scrambler B PCR 
product was first cloned into a pGEM-T Easy vector (Promega), then isolated with a SacII 
digest and ligated into the targeting vector. Diagnostic NotI, HindIII/XhoI and SacII 
restriction digests were performed. 
2.2 Extension the SdhB targeting vector 
A forward primer specific for SdhB intron seven that contains the SalI restriction site (LJM-
2599: ATATGTG2TCAGTGCT4C) and a reverse primer specific for a region downstream of 
SdhB exon eight that contains a NotI restriction site (LJM-2595: GCTAGCGCG2-
C2GC2TA2CTCACG2A2G3CA2G2) were used to amplify a Scrambler B extension product by 
PCR (Epicentre, Failsafe kit). The product was cloned into the original targeting vector using 
standard procedures. 
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2.3 ES cell culture and transfection with targeting vectors 
ES cells derived from C57BL/6 blastocysts (E3.5) were transfected with NotI linearized 
targeting vectors, and stable integrants were selected in Geneticin G418 medium as 
described (Hofker & van Deursen, 2002). 
2.4 Southern blotting 
PCR was used to generate a 200-bp probe with homology to intron two of the SdhB gene. 
The probe was labeled by random priming in the presence of [ǂ−32P]-dATP according to 
manufacturer’s instructions (Roche). 10-20 μg of genomic DNA from ES cell clones was 
digested with SacI (New England Biolabs) and the DNA was electrophoresed overnight at 
40 V. Southern blotting of DNA was performed using standard procedures as described 
(Hofker & van Deursen, 2002).  
2.5 Genetic analysis of 129SV/E SdhB:β-Geo disrupted ES cells 
For expression analysis by RT-PCR RNA was harvested from SdhB +/- ES cells with Trizol 
reagent by standard procedures, and reverse transcribed with a pool of nonamers according 
to manufacturer’s instructions (Epicentre). cDNA was amplified with a common forward 
primer specific to SdhB exon one (LJM-2684: CGACG2TCG3TCTC2T2GA2) and either a β-Geo-
specific reverse primer (LJM-2687: AT2CAG2CTGCGCA2CTGT2G3) or an exon two-specific 
reverse primer (LJM-2685: GAGCTGCAGCAGCAGCTGTC) by PCR (Epicentre, Failsafe 
kit). For mapping of the gene integration point by PCR genomic DNA from SdhB +/- ES 
cells was precipitated with lysis/precipitation buffer [50 mM Tris-HCl (pH 8.0), 100 mM 
EDTA (pH 8.0), 100 mM NaCl, 1% SDS, 10 mg/ml proteinase K] and extracted with 
phenol:chloroform (1:1). A forward primer specific for SdhB exon one (LJM-2784: 
AGCTGAC2AGACA2GAGTCACAG2TGAT2GACAGA) and a reverse primer specific for the 
β-Geo marker (LJM-2787: AGTATCG2C2TCAG2A2GATCGCACTC2AGC2AGC) were used to 
amplify the region of the gene trap vector integration by PCR (Epicentre, Failsafe kit). The 
PCR product was purified and sequenced across the β-Geo marker to verify the exact SdhB:β-
Geo junction. 
2.6 Generation and husbandry of mice 
Following genetic characterization, SdhB +/- ES cells were injected into C57/BL6 blastocysts 
and used to generate chimeric animals as described (Hofker & van Deursen, 2002). Animals 
were caged in groups of five, segregated by genotype and gender. Standard animal 
husbandry methods were used under IACUC protocol A29505 in the Mayo Clinic non-
barrier mouse facility. 
2.7 DNA extraction 
DNA extraction from tail clippings was performed after overnight digestion in 
lysis/precipitation buffer [50 mM Tris-HCl (pH 8.0), 100 mM EDTA (pH 8.0), 100 mM NaCl, 
1% SDS, 10 mg/ml proteinase K] at 55°C. DNA was precipitated with isopropanol, washed 
once in 80% ethanol and resuspended in sterile water. 
2.8 Genotyping 
To distinguish SdhB +/+ and SdhB +/- animals, genomic DNA was analyzed by PCR 
(Epicentre, Failsafe kit) with a common forward primer LJM-2826 (5’-
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GTGTAGC3TG2CTGTC2TG2A2CT2GCTC) and differential reverse primers, LJM-2828 (5’-
G2CA3C3A4G3TCT3GAGCAC2AG) and LJM-2830 (5’-GTG3AC2TGCGTGACA3GT 
GCATG2AG), specific for β-Geo and intron one, respectively. Bub1 Genotyping used 
standard PCR methods employing the Failsafe kit (Epicentre). The Bub1 WT locus was 
amplified with a forward primer in exon eight (LJM-3169: CTG2C2TG2A2CT2GCTATGTC) 
and a reverse primer in intron eight (LJM-3171: CG2T3CTCTGTATAGC3TG2C). The Bub1 
knockout allele was amplified with a forward primer in the neomycin cassette (LJM-3178: 
GCAGT2CAT2CAG3CAC2G2AC) and the reverse primer LJM-3171. The Bub1 hypomorphic 
allele was amplified with a primer set in the hygromycin cassette (forward primer, LJM-
3172: CG2A2GTGCT2GACAT2G2; reverse primer, LJM-3173: GTAT2GAC2GA-T2C2T2GCG). 
2.9 Histology 
Tissue samples for histology were dissected and fixed in neutral-buffered 10% formalin 
(Sigma) for 24 h. Tissues were dehydrated, embedded in paraffin, and 10-µm slices were 
prepared with a microtome and mounted. Standard hematoxylin and eosin staining was 
used for initial histopathology. Bifurcations containing carotid bodies were dissected and 
fixed in formalin (Sigma) at 4°C for 16 h. Tissues were dehydrated and paraffin embedded, 
and 10-µm slices were obtained by using an RM2125 microtome (Leica Microsystems). 
Immunohistochemistry was performed according to standard procedures. For detection of 
glomus cells, tissues were immunostained with a rabbit polyclonal antityrosine hydroxylase 
(TH) antibody (Pel-Freez). After immunodetection with peroxidase-conjugated secondary 
antibody, tissue samples were counterstained with hematoxylin. 
2.10 Quantitative RNA analysis by RT-PCR 
RNA from liver or kidney tissue was harvested with the RNeasy Plus Mini kit (Qiagen), 
quantitated with a RiboGreen assay (Invitrogen) and reverse transcribed by random 
nonamers (Epicentre). cDNA was amplified by PCR (BioRad IQ SuperMix) with a forward 
primer (LJM-3115: ATGA2CATCA2CG2AG2CA2TAC) and a reverse primer (LJM-3116: 
GAG3TAGAT4G2AGACT3GC) located downstream of the ǃGEO insertion site in exon four. 
Probe 5’-6-FAM/CACACGCAG2ATCGACACG2AC2T/3BHQ-1 specific for exon four was 
used to monitor target amplification of either cDNA or an 82-bp synthetic DNA amplicon 
used to produce a standard curve in a BioRad iCycler.  
2.11 Enzyme assays 
SDH activity was assayed in kidney and liver extracts from juvenile mice of each genotype 
euthanized by cervical dislocation. SDH activity was measured as PMS-mediated reduction 
of the 2,6-dichloroindophenol dye in the presence of antimycin A, rotenone and cyanide, 
monitored at 600 nm as described (Kramer et al., 2005).  
2.12 Metabolite analysis 
Levels of TCA cycle metabolites were determined by acidification of urine and extraction of 
free acids into ethyl acetate. 2-keto acids (e.g. 2-KG) were first protected by oximation with 
hydroxylamine hydrate. After evaporation, the dry residue was silyated with N,O-bis-
(trimethylysilyl)trifluoroacetamide and trimethylchlorosilane to produce volatile 
derivatives, and analyzed by capillary gas chromatography/mass spectrometry on an HP 
ChemStation instrument equipped with an HP-5 25 m column (ID 0.2 mm) using 
pentadecanoic acid as an internal standard. Metabolite levels were normalized to creatine. 
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3. Results 
3.1 Generation of SdhB +/- mice 
Two approaches were initially taken to generate an SdhB +/- mouse strain (Fig. 3). The first 
strategy involved the creation of a DNA targeting vector that would specifically replace part 
of exon three through part of intron four by homologous recombination with a neomycin 
resistance marker on a single SdhB allele (Fig. 3A). The targeting vector carried two arms of 
homology to SdhB (Scrambler A and Scrambler B) and two selectable markers – NEO 
(neomycin phosphotransferase) and TK (thymidine kinase) genes. These genes allow for 
selection of integrants and counterselection against non-homologous insertions, 
respectively. This construct was intended to exchange the selectable NEO marker for a 
segment of SdhB extending from part of exon 3 through part of intron 4. This strategy would 
create an SdhB mRNA with only a short reading frame, followed by nonsense codons. The 
resulting truncated polypeptide is analogous to loss-of-function products seen in human 
SdhB mutations causing PGL (Benn et al., 2006).  
The targeting vector was constructed and verified with diagnostic restriction digests that 
confirmed the successful insertion and orientation of both SdhB homology regions into the 
targeting vector. Its size (13.6 kb) was confirmed by linearization with NotI, Scrambler A 
insertion was confirmed by a HindIII/XhoI digest, and Scrambler B insertion was confirmed 
by a SacII digest. Molecular junctions were sequenced to confirm expected features of the 
targeting vector. 
Mouse ES cells were electroporated with the linearized SdhB targeting vector, and 
NEO+ TK- colonies were selected and screened for targeted inactivation of one copy of 
SdhB. DNA was harvested from over 400 potential clones and analyzed by Southern 
blot. None of the clones showed evidence of homologous recombination at SdhB. 
Similar results were obtained even when the Scrambler B SdhB homology segment was 
increased in length. 
We therefore adopted a second strategy (Fig. 3B). We obtained an SdhB +/- embryonic 
stem (ES) cell line that had been created by high throughput random gene trap integration 
by the Sanger Center gene trap consortium (Nord et al., 2006). Sequencing of an RT-PCR 
product derived from the integrated β-Geo marker gene revealed integration of the gene 
trap cassette in intron 1 of the mouse SdhB gene. The strong cleavage and poly(A) signals 
of the gene trap fragment should truncate SdhB mRNA after the short exon 1, resulting in 
a completely non-functional SdhB mRNA, analogous to that produced by disease-
associated truncating alleles in humans. We confirmed the presence of the gene trap by 
PCR from random-primed cDNA prepared from the ES cells. PCR of genomic DNA from 
the ES cell line allowed us to map the precise location of the gene trap, and sequencing of 
PCR products showed the exact position of the trap reporter gene downstream of the exon 
1/intron 1 junction (Fig. 4A).  
The SdhB +/- ES cells were injected into blastocyts that were then implanted in 
pseudopregnant females. Multiple chimeric offspring were obtained, four of which 
transmitted the mutant SdhB allele in their germ lines. These founders were mated with 
C57BL/6 strain females. A PCR screening procedure was developed (Fig. 4B) to allow 
genotyping of (129SV/E x C57BL/6)F1 offspring generated from SdhB +/+ x chimeric SdhB 
+/- matings. This approach proved successful for generating the desired SdhB +/- mouse 
strain used to develop a colony of 55 SdhB +/+ and 55 SdhB +/- mice. 
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Fig. 3. SdhB knockout strategies. A. Targeted knockout approach. A targeting vector with 
homology regions encompassing intron two through part of exon three (shaded A) and 
encompassing part of intron four through intron seven (shaded B) flanking a neomycin 
cassette was used to target the WT SdhB locus and generate a disrupted SdhB locus. 
Numbers indicate position in SdhB locus from transcription start site. B. Gene trap vector 
approach. Gene trap vector contains a splice acceptor (SA) site upstream of the ǃGEO 
cassette (encodes ǃ-galactosidase−neomycin phosphotransferase fusion protein) followed by 
a strong polyadenylation (pA) site inserted into intron one of SdhB. The SA site of the ǃGEO 
cassette will replace the SA site of exon two and will be spliced with the splice donor site of 
exon one.  
 
Fig. 4. SdhB genotyping PCR design. A. Schematic diagram showing the SdhB locus with or 
without a ǃGEO insertion in intron one. Primer set A/C amplifies the 912 bp WT locus and 
primer set A/B amplifies 439 bp from the disrupted locus. Numbers indicate position from 
the transcription start site in the wild type SdhB locus. B. PCR genotyping agarose gel 
showing SdhB +/+ vs. SdhB +/- amplification products from genomic DNA. 
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3.2 Characterization of SdhB +/- mice 
We determined the viability of SdhB -/- mice. We hypothesized that the SdhB -/- condition 
would not support mammalian development due to lack of TCA cycle function. To test this 
hypothesis we crossed SdhB +/- heterozygotes and examined the genotypes of progeny. In 
the absence of SdhB -/- offspring, the prediction from Mendelian genetics is tbat 1/3 of 
progeny will be SdhB +/+ WT and 2/3 will be SdhB +/- heterozygotes. Breeding to test this 
hypothesis was performed until 107 offspring were genotyped. These offspring included 35 
SdhB +/+ mice, 72 SdhB +/- mice with no SdhB(-/-) mice observed. This result implies that 
the SdhB -/- condition has an embryonic lethal phenotype. Indeed, it was previously 
reported that SdhD -/- mice die at 6.5 to 7.5 days post conception (Piruat et al., 2004). 
Evidence suggests that SdhB -/- mice also die around the time of organogenesis. 
SdhB +/- mouse tissues were then characterized in terms of SdhB gene expression and SDH 
enzyme activity (Fig. 5).  
 
 
Fig. 5. Characterization of SdhB +/+ and SdhB +/- mice. A. SdhB expression levels (n=5). B. 
SDH activity (n=5). C. TCA metabolite levels in urine (n=3). 1, succinate; 2, fumarate; 3, 
malate; 4, citrate; 5, aconitate. Error basis indicates SEM. D. Results of 24-h urine 
normetanephrine screening in WT and SdhB +/- mice.  
It was previously reported that SdhD +/- mice have a 50% decrease in SdhD expression and 
SDH activity (Piruat et al., 2004). We characterized SdhB expression and SDH activity in the 
liver and kidneys of SdhB +/- mice relative to SdhB +/+ mice. These organs have high 
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metabolic activity and are easily homogenized for assays. We found that SdhB gene 
expression was decreased by 50% (based on quantitative RT-PCR analysis; Fig. 5A). In 
contrast, no difference in SDH enzyme activity was detected in these tissues (Fig. 5B), 
suggesting translational compensation or other homeostatic mechanisms. Furthermore, TCA 
cycle metabolites (He et al., 2004) in tissue (Fig. 5C) and metanephrines in urine (Fig. 5D) 
were not different between mice with SdhB+/+ and SdhB+/- genotypes. 
 
 
Fig. 6. Weight analysis for SdhB +/+ and SdhB +/- mice, by gender: A. Females. B. Males. 
The box represents the middle 50% of the weights (25-75%) and the horizontal bar 
represents the median weight for each group. The dashed lines encompass the remainder of 
the data, excluding outliers represented by circles. 
Animals in the experimental colony were monitored by abdominal palpation and weight 
measurement. No abnormalities were detected in SdhB +/- animals. No significant 
differences were observed for weights of SdhB +/+ and SdhB +/- mice (Fig. 6). After one 
year, six SdhB +/+ and six SdhB +/- mice were euthanized and reviewed for gross and 
microscopic pathology of adrenal glands, heart, liver, lung, and kidneys. A detailed 
pathological analysis of carotid bodies investigated the possibility of neuroendocrine cell 
hypertrophy as has been suggested for SdhD +/- heterozygotes (Piruat et al., 2004). The 
results are shown in Fig. 7. Although there was a trend towards smaller carotid body size in 
SdhB +/- heterozygotes (Fig. 7A), the trend was not statistically significant (p values > 0.05 
by t-test). This trend came mainly from male mice. Neuroendocrine cells of the carotid 
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bodies of males were detected by tyrosine hydroxylase (TH) staining. Again, a trend toward 
a reduced number of type I (TH+) cells was observed in the SdhB +/- carotid bodies (Fig. 
7B). Again, this difference was not statistically significant. There was no carotid body 
hypertrophy or any sign of hyperproliferation (Fig. 7C). No PGL or PHEO tumors were 
observed in any mice, even in compound SdhB +/- SdhD +/- heterozygotes. 
 
 
Fig. 7. Mouse carotid body pathology. A. Observed trend toward smaller carotid body size 
in SdhB +/- mice, not reaching statistic significance by t-test. The contribution to this trend 
comes mainly from males. B. Analysis of tyrosine hydroxylase positive (TH+) cells in carotid 
bodies from males. The trend toward a reduced number of TH+ cells in SdhB +/- male mice 
does not reach statistical significance. C. Examples of carotid body pathology. There is no 
evidence of carorid body hypertrophy or hyperproliferation in SdhB +/- mice. 
3.3 Generation of SdhB +/- Bub1 H/- mice 
We hypothesized that the absence of PGL in SdhB +/- mice was due to the low rate of SdhB 
LOH. We therefore sought genetic methods to enhance this rate. Aneuploidy (abnormal 
chromosome content) is a hallmark of most solid tumors and cancer cell lines (Heim & 
Mitelman, 1995; Lengauer et al., 1997; Lengauer et al., 1997). Over 100 years ago Theodor 
Boveri postulated that chromosome instability (CIN) drives tumorigenesis. CIN is believed 
to be frequently responsible for TSG LOH (Bignold et al., 2006; Kops et al., 2005). More than 
100 CIN genes have been identified in yeast (Kolodner et al., 2002; Nasmyth, 2002; Shonn et 
al., 2000). A novel mammalian gene of this type is Bub1 (mouse chromosome 2), which plays 
a key role in the mitotic checkpoint.  
Mitotic checkpoint proteins survey proper kinetichore attachment during mitosis. When the 
mitotic spindle is correctly attached to all kinetochores, Cdc20 activates the anaphase 
promoting complex (APC) to degrade securin, allowing release of separase to “unbind” 
sister chromatids and promote the transition from metaphase to anaphase (Kops et al., 
2005). Mitotic checkpoint proteins produce a “stop anaphase” signal when kinetochores are 
not properly attached to the mitotic spindle during prometaphase. An APC inhibitory 
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complex is involved (Kops et al., 2005; Shah & Cleveland, 2000; Wang et al., 2001). The BUB1 
protein has three putative molecular functions in this mitotic checkpoint (Acampora et al., 
1999) as illustrated in Fig. 8. 
 
 
Fig. 8. Putative functions of Bub1 in mitosis. 1. Bub1 mediates Mad1/Mad2 binding to 
kinetochores, which allows for efficient formation of APC inhibitory complexes consisting of 
Mad2, BubR1, and Bub3. The APC inhibitory complex functions by sequestration of Cdc20. 
2. Bub1 phosphorylates Cdc20, thereby preventing APC activation. 3. Bub1 is required for 
stability and centromeric localization of centromeric cohesin. 
Loss of Bub1 expression was predicted to result in aneuploidy and increased tumorigenesis. 
In support of this hypothesis, Bub1 mutations were detected in 2/19 colorectal cancer cell 
lines with CIN (Cahill et al., 1998) and epigenetic silencing of Bub1 is a frequent event in 
human colorectal carcinomas, with 30% exhibiting at least two-fold reduction in Bub1 
expression (Shichiri et al., 2002). In addition, Bub1 mutations have been correlated with lung, 
pancreatic and rectal cancers (Gemma et al., 2000; Hempen et al., 2003; Imai et al., 1999).  
The van Deursen laboratory has developed a series of mouse strains in which expression of 
Bub1 protein is reduced in a graded fashion by different combinations of wild type, 
knockout, and hypomorphic alleles (Jeganathan et al., 2007). The Bub1 hypomorphic allele 
[Bub1(H)] results from intron 9 insertion of the hygromycin B phosphotransferase gene 
(Hyg), resulting in a high level of premature transcription termination (van Deursen et al., 
1994). Standard procedures and breeding yielded Bub1 +/H, Bub1 H/H, and Bub1 H/- 
viable offspring. Western blotting showed graded reduction of Bub1 levels across these 
strains in mouse embryonic fibroblasts.  
Of the mice in the Bub1 genotype series, the Bub1 H/- strain shows the most dramatic 
phenotype. Bub1 H/- mice display increased aneuploidy and tumorigenesis relative to the 
other Bub1 genotypes. Analysis of 150 mitotic figures from Bub1 H/- splenocytes showed 
39% aneuploidy, compared to only 1% aneuploidy in Bub1 +/+ animals (Jeganathan et al., 
2007). Bub1 H/- animals also suffer more tumors (52% tumor incidence in 530 days) than 
Bub1 +/+ animals (33% tumor incidence in 772 days). Lymphoma and sarcoma incidence 
was higher and hepatocellular carcinoma incidence lower for Bub1 H/- animals than for 
wild type animals. 
Mutations in CIN genes can increase the rate of loss of entire chromosomes or chromosome 
segments during cell division, thereby accelerating LOH of tumor suppressor genes (Cahill 
et al., 1999; Cahill et al., 1998; Jallepalli & Lengauer, 2001). Indeed, it was shown in a cohort 
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of 30 Bub1 H/- p53 +/- animals monitored for 100 days that 5 mice developed tumors. In 
contrast, 0/30 age-matched p53 +/- mice developed tumors during the same time period 
(Jeganathan et al., 2007). All tumors in Bub1 H/- p53 +/- mice were thymic lymphomas, the 
most common tumor form in p53(-/-) mice (Donehower et al., 1992; Donehower et al., 1995; 
Jacks et al., 1994). Accelerated tumorigenesis resulted from p53 LOH as shown by PCR 
analysis of DNA from Bub1 H/- p53 +/- lymphomas (Jeganathan et al., 2007; Jacks et al., 
1994). 
A two-part breeding program created a colony of 55 SdhB +/- Bub1 H/- compound 
heterozygote mice (Fig. 9). In part 1, SdhB +/– females were crossed with Bub1 H/- males to 
generate offspring of four genotypes (Fig. 9A). In part 2, offspring of these matings were 
crossed to generate the desired SdhB +/-Bub1 H/- animals at the indicated expected 
frequencies (Fig. 9B). Multiplex PCR genotyping was developed to distinguish Bub1 +, H 
and – alleles (Fig. 9C). The colony of SdhB +/- Bub1 H/- compound heterozygote mice was 
monitored for PGL tumorigenesis. Age-dependent survival of this and related strains is 
shown in Fig. 10. As had been observed for SdhB +/- mice, no PGL tumors were observed in 
SdhB +/- Bub1 H/- animals. 
 
 
Fig. 9. SdhB +/- Bub1 H/- breeding scheme. A. Initial cross providing offspring for brother-
sister matings. B. Brother-sister mating scheme from (A), indicating expected frequencies of 
the desired SdhB +/- Bub1 H/- genotype among offspring. Allele abbreviations: SdhB WT: 
D; SdhB gene trap disruption: d; Bub1 WT: B; Bub1 hypomorph, H; Bub1 disruption: (-). C. 
Bub1 Genotyping PCR design. Schematic diagram showing the Bub1 locus with or without a 
hygromycin (hypomorphic allele) or neomycin (knockout allele) insertion. Primers used to 
amplify the alleles are designated by arrowheads. 
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Fig. 10. Kaplan-Meier plot of mouse survival data. 
4. Discussion  
Spontaneous PGL is rare in mice (Jacks et al., 1994; Jacks et al., 1994). In a mouse model of 
human neurofibromatosis type 1, a dominant disease caused by inheritance of a mutant 
allele of NF1, a modest incidence of PHEO was observed (Jacks et al., 1994), but this genetic 
pathway to PGL appears unrelated to tumor suppression by Sdh genes. 
We hypothesized that SdhB +/- mice would be predisposed to familial PGL. This hypothesis 
was based on the prevailing evidence that the SdhB +/- genotype predisposes humans to 
PGL, with high penetrance. We therefore developed a strain of SdhB +/- mice using mouse 
stem cells carrying a gene trap insertion in intron 1 of SdhB. Using these animals we showed 
that, as anticipated, the SdhB -/- genotype is not viable. Although we found that there is a 
significant reduction of SdhB expression in tissues of SdhB +/- mice relative to SdhB +/+ 
mice, there was no difference in SDH activity between the two groups in either liver or 
kidney. These results suggest that there is no phenotypic difference between SdhB +/- and 
SdhB +/+ mice, consistent with the absence of phenotype for humans heterozygous for Sdh 
germline mutations. However, unlike humans where there is high penetrance of PGL in 
SdhB +/- individuals, no PGL tumors were detected in SdhB +/- mice. 
LOH of a TSG can be the rate-limiting step in tumor development (Lasko et al., 1991; Luo et 
al., 2000). The mechanism for LOH is not completely understood but involves chromosome 
loss, deletion and/or homologous interchromosomal mitotic recombination events (Henson 
et al., 1991; Shao et al., 2000; Stark & Jasin, 2003). Mitotic recombination refers to the 
reciprocal exchange of genetic material between nonsister chromatids in mitotic cells. 
Mitotic recombination occurs at a high frequency in humans and mice (Gupta et al., 1997; 
Holt et al., 1999; Shao et al., 1999). It has been suggested that mitotic recombination is the 
predominant pathway to LOH (Gupta et al., 1997; Luo et al., 2000; Shao et al., 1999; Shao et 
al., 2000).  
Because mitotic recombination requires high nucleotide sequence homology, chromosomal 
divergence suppresses mitotic recombination and may modify cancer development by 
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lowering the rate of LOH (Shao et al., 2001). The use of inbred strains in this study (C57BL/6 
x 129SVE)F1 should promote mitotic recombination. It has also been found that the 
spontaneous frequency of mitotic recombination increases with age (Grist et al., 1992). The 
penetrance of SdhB mutations in familial PGL is estimated to be 50% at age 30 and 
approaches 100% after 60 years of age (Neumann et al., 2004).  
To address the possible limitation of LOH in converting somatic neuroendocrine cells from 
SdhB +/- to SdhB -/-, we developed a mouse colony of SdhB +/- mice bred onto the Bub1 
H/- genetic background previously shown to enhance aneuploidy. PGL tumorigenesis was 
not observed in this strain. 
There are at least three possible explanations for these results. First, it is possible that the 
rate of somatic LOH at SdhB in neuroendocrine cells remains insufficient to drive PGL 
tumorigenesis within the lifespan of mice. Second, it is possible that PGL tumorigenesis 
takes place in SdhB +/- mice, but the subsequent rate of tumor growth is too slow to permit 
tumor detection within the mouse lifespan. Finally, it is possible that SdhB is not a tumor 
suppressor in murine PGL. 
If either of the first two explanations are correct, it might be possible to enhance the rate of 
PGL tumorigenesis by developing a conditional knockout mouse strain where both copies of 
the Sdh gene for one SDH subunit are replaced by a knock-in construct that can be 
recombinationally inactived upon expression of a recombinase. Unlike standard conditional 
knock-out designs, it would be important to delete the Sdh subunit gene only at very low 
frequency, since most affected tissues would presumably be damaged by loss of the TCA 
cycle. Rather, an inefficient recombination that eliminated SDH in perhaps 1% of cells might 
be appropriate. This might be achieved either by low levels of neuroendocrine-specific 
expression of recombinase (e.g. from the tyrosine hydroxylase promoter), or by low levels of 
global recombinase expression. Unfortunately, mouse strains are not yet available for tissue-
specific CRE expression in neuroendocrine cells.  
Either low-efficiency conditional knockout strategy offers the prospect of dramatically 
increasing the early generation of neuroendocrine cells lacking SDH activity. Such a model 
would be hypothesized to increase the frequency of tumorigenesis, and allow a longer 
period for tumor growth. 
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